Ali Yılmaz Altay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ali Yılmaz Altay has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Gülçin Yeğen
İstanbul University, İstanbul Faculty of Medicine, Department of Pathology, İstanbul, Türkiye
3 shared publications - Ipek Yonal-Hindilerden
Istanbul University Faculty of Medicine, Department of Adult Hematopoietic Stem Cell Transplantation Unit, Istanbul, Turkey
3 shared publications - Metban Mastanzade
Istanbul Medical Faculty, Department of Hematology Istanbul University Istanbul Turkey
3 shared publications - Murat Ozbalak
Istanbul Medical Faculty, Department of Hematology Istanbul University Istanbul Turkey
3 shared publications Ekrem Yavuz
Istanbul Univ, Dept Pathol, Istanbul Fac Med, Istanbul, Turkiye
2 shared publications- Ezgi Pinar
Division of Geriatrics, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey
2 shared publications
Latest Publications
- Open Access
- 30 August 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (6) , 1659-1664
Bone Marrow Fibrosis as a Predictor of Extramedullary Disease in Multiple Myeloma
The correlation between bone marrow fibrosis (BMF) and extramedullary disease has yet to be fully elucidated in patients with newly diagnosed multiple myeloma. Therefore, we aimed to analyze the incidence of BMF in newly diagnosed multiple myeloma patients and evaluate the relationship between BMF and synchronous soft tissue extramedullary involvement at diagnosis. A retrospective chart review was conducted on a total of 356 patients with multiple myeloma. Patients' clinical characteristics, treatment outcomes, and histological features were systematically collected. The degree of BMF was graded according to the World Health Organization criteria. Patients with Grade 2 and 3 BMF were classified into the fibrosis group, whereas those with Grade 0 or 1 were categorized into the non‐fibrosis group. Extramedullary disease was defined as soft tissue tumors arising from hematogenous spread without any contiguous contact with bony structures. Finally, clinical and laboratory parameters were compared between the fibrosis and non‐fibrosis groups. Of the 356 patients, 146 (41%) presented with Grade 2 or higher levels of BMF. Extramedullary disease was detected in 52 patients (14.6%), while 54 patients (15.2%) had paraskeletal plasmacytoma. Grade 2 or 3 BMF was observed in 40 of the 52 patients with extramedullary disease ( p < 0.01). Consistently, in the 210 patients without BMF, EMD was absent in 198 cases ( p < 0.01). In multivariable logistic regression analysis, BMF status (OR = 3.200, 95% CI: 1.010–10.141, p = 0.048) and elevated serum lactate dehydrogenase (LDH) levels (OR = 1.003, 95% CI: 1.000–1.005, p = 0.037) were identified as independent predictors of synchronous extramedullary disease. In conclusion, our study indicates that increased BMF in patients with multiple myeloma is closely associated with synchronous extramedullary dissemination. Consequently, evaluating BMF at initial diagnosis may serve as a useful surrogate marker to identify patients presenting with concurrent extramedullary involvement.
- 30 August 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (6) , 1659-1664
Open AccessBone Marrow Fibrosis as a Predictor of Extramedullary Disease in Multiple Myeloma
The correlation between bone marrow fibrosis (BMF) and extramedullary disease has yet to be fully elucidated in patients with newly diagnosed multiple myeloma. Therefore, we aimed to analyze the incidence of BMF in newly diagnosed multiple myeloma patients and evaluate the relationship between BMF and synchronous soft tissue extramedullary involvement at diagnosis. A retrospective chart review was conducted on a total of 356 patients with multiple myeloma. Patients' clinical characteristics, treatment outcomes, and histological features were systematically collected. The degree of BMF was graded according to the World Health Organization criteria. Patients with Grade 2 and 3 BMF were classified into the fibrosis group, whereas those with Grade 0 or 1 were categorized into the non‐fibrosis group. Extramedullary disease was defined as soft tissue tumors arising from hematogenous spread without any contiguous contact with bony structures. Finally, clinical and laboratory parameters were compared between the fibrosis and non‐fibrosis groups. Of the 356 patients, 146 (41%) presented with Grade 2 or higher levels of BMF. Extramedullary disease was detected in 52 patients (14.6%), while 54 patients (15.2%) had paraskeletal plasmacytoma. Grade 2 or 3 BMF was observed in 40 of the 52 patients with extramedullary disease ( p < 0.01). Consistently, in the 210 patients without BMF, EMD was absent in 198 cases ( p < 0.01). In multivariable logistic regression analysis, BMF status (OR = 3.200, 95% CI: 1.010–10.141, p = 0.048) and elevated serum lactate dehydrogenase (LDH) levels (OR = 1.003, 95% CI: 1.000–1.005, p = 0.037) were identified as independent predictors of synchronous extramedullary disease. In conclusion, our study indicates that increased BMF in patients with multiple myeloma is closely associated with synchronous extramedullary dissemination. Consequently, evaluating BMF at initial diagnosis may serve as a useful surrogate marker to identify patients presenting with concurrent extramedullary involvement.
- 24 August 2026
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 85
ERG and CD31 expression in acute megakaryoblastic leukemia and myeloid sarcoma: A diagnostic pitfall
- 24 August 2026
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 85
ERG and CD31 expression in acute megakaryoblastic leukemia and myeloid sarcoma: A diagnostic pitfall
- Open Access
- 10 March 2025
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 42 (2) , 153-155
A Rare Case of Non-Hodgkin Lymphoma Presenting as a Mass Originating from the Corpus Cavernosum
Malignant neoplasms of the penis are uncommon, the most common being squamous cell carcinoma. Non-Hodgkin's lymphoma occurs in extranodal sites in half of patients, but is extremely rare in the penis. Here, a 24 years old case of a penile mass is reported as non-Hodgkin lymphoma. On physical examination and imaging, two-centimeter lesion was detected on the left distal corpus cavernosum of the penis and extending to the proximal corpus cavernosum. Excisional biopsy from distal left corpus cavernosum performed under general anesthesia. Histopathological examination of the excision material revealed diffuse large B-cell lymphoma with a post-germinal center cell phenotype. Although it is rare in patients presenting with a penile mass, the possibility of lymphoma involvement should be kept in mind. It can mimic Peyronie's disease or corpus cavernosum thrombosis.
- 10 March 2025
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 42 (2) , 153-155
Open AccessA Rare Case of Non-Hodgkin Lymphoma Presenting as a Mass Originating from the Corpus Cavernosum
Malignant neoplasms of the penis are uncommon, the most common being squamous cell carcinoma. Non-Hodgkin's lymphoma occurs in extranodal sites in half of patients, but is extremely rare in the penis. Here, a 24 years old case of a penile mass is reported as non-Hodgkin lymphoma. On physical examination and imaging, two-centimeter lesion was detected on the left distal corpus cavernosum of the penis and extending to the proximal corpus cavernosum. Excisional biopsy from distal left corpus cavernosum performed under general anesthesia. Histopathological examination of the excision material revealed diffuse large B-cell lymphoma with a post-germinal center cell phenotype. Although it is rare in patients presenting with a penile mass, the possibility of lymphoma involvement should be kept in mind. It can mimic Peyronie's disease or corpus cavernosum thrombosis.
- Open Access
- 31 October 2024
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 42 (1) , 9-14
GATA3 Immunohistochemical Staining in Classical Hodgkin Lymphoma and its Diagnostic Utility in Differential Diagnosis
Classical Hodgkin lymphoma (CHL) is a common lymphoid neoplasm with a wide range of differential diagnosis. Although it has a specific immunophenotype, aberrant expression of antigens can cause problems at its diagnosis. In this study we evaluated the usefulness of GATA3 in differential diagnosis of classical Hodgkin lymphoma. One hundred CHL cases and a control group of 106 lymphoma cases, which include anaplastic large cell lymphoma (ALK (+) and (-)), EBV (+) large B cell lymphoma, T-cell/ histiocyte rich B cell lymphoma, primary mediastinal large B cell lymphoma, nodular lymphocyte predominant Hodgkin lymphoma and mediastinal grey zone lymphoma, were included in the study. GATA3 immunohistochemistry were applied to all cases and its nuclear expression was accepted as positive. Expression status of GATA3 was compared in between the CHL and the control group, as well as among each lymphoma subtype. In addition, whether the biopsy type effects its diagnostic performance is assessed. In CHLs relationship with EBV status and GATA3 expression is evaluated. GATA3 expression was significantly higher in CHL cases compared to the control group (p<0,001). When compared with the individual subgroups GATA3 is still found to be useful in differential diagnosis except for ALK (-) ALCL (p=0,678) and mediastinal gray zone lymphomas (p=0,327). GATA3 expression is significantly higher in EBV (-) CHLs (p=0,02). In core needle biopsies its diagnostic performance is limited (p=0,178). GATA3 is a useful marker for differentiating CHL from B-cell non-Hodgkin lymphomas but its efficiency is limited in ALK (-) ALCL and mediastinal grey zone lymphomas. Due to the heterogeneous reaction diagnostic value is limited in core needle biopsies.
- 31 October 2024
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 42 (1) , 9-14
Open AccessGATA3 Immunohistochemical Staining in Classical Hodgkin Lymphoma and its Diagnostic Utility in Differential Diagnosis
Classical Hodgkin lymphoma (CHL) is a common lymphoid neoplasm with a wide range of differential diagnosis. Although it has a specific immunophenotype, aberrant expression of antigens can cause problems at its diagnosis. In this study we evaluated the usefulness of GATA3 in differential diagnosis of classical Hodgkin lymphoma. One hundred CHL cases and a control group of 106 lymphoma cases, which include anaplastic large cell lymphoma (ALK (+) and (-)), EBV (+) large B cell lymphoma, T-cell/ histiocyte rich B cell lymphoma, primary mediastinal large B cell lymphoma, nodular lymphocyte predominant Hodgkin lymphoma and mediastinal grey zone lymphoma, were included in the study. GATA3 immunohistochemistry were applied to all cases and its nuclear expression was accepted as positive. Expression status of GATA3 was compared in between the CHL and the control group, as well as among each lymphoma subtype. In addition, whether the biopsy type effects its diagnostic performance is assessed. In CHLs relationship with EBV status and GATA3 expression is evaluated. GATA3 expression was significantly higher in CHL cases compared to the control group (p<0,001). When compared with the individual subgroups GATA3 is still found to be useful in differential diagnosis except for ALK (-) ALCL (p=0,678) and mediastinal gray zone lymphomas (p=0,327). GATA3 expression is significantly higher in EBV (-) CHLs (p=0,02). In core needle biopsies its diagnostic performance is limited (p=0,178). GATA3 is a useful marker for differentiating CHL from B-cell non-Hodgkin lymphomas but its efficiency is limited in ALK (-) ALCL and mediastinal grey zone lymphomas. Due to the heterogeneous reaction diagnostic value is limited in core needle biopsies.
- 3 July 2023
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 19 (3) , 253-256
Ductal Carcinoma In Situ Arising in Sentinel Axillary Lymph Nodes Excised From Patients With Breast Carcinoma - A Potential Diagnostic Pitfall. Report of Two Cases
We present two cases of ductal carcinoma in situ (DCIS) that arose in axillary lymph nodes excised as the sentinel lymph node from two patients with breast carcinoma. The patient ages were 72 and 36 years and both patients underwent mastectomy and axillary lymph node dissection. In addition to DCIS in the sentinel lymph node, the first patient had a wide DCIS and microinvasion in the ipsilateral breast and a micrometastasis in another sentinel lymph node. The second patient was operated on after neoadjuvant chemotherapy and had DCIS and a small focus of invasion, in addition to invasive and in situ ductal carcinoma in the lymph node having signs of chemotherapy-induced regression. The presence of DCIS was confirmed by use of the immunohistochemical method with antibodies against myoepithelial cells. As a potential source of cellular origin, DCIS was accompanied by benign epithelial cell clusters in the lymph node in both cases. Morphologic and immunohistochemical features were similar in breast and lymph node neoplasms. We conclude that DCIS may rarely develop from benign epithelial inclusions in the axillary lymph node and is a potential diagnostic pitfall in cases having ipsilateral breast carcinoma.
- 3 July 2023
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 19 (3) , 253-256
Ductal Carcinoma In Situ Arising in Sentinel Axillary Lymph Nodes Excised From Patients With Breast Carcinoma - A Potential Diagnostic Pitfall. Report of Two Cases
We present two cases of ductal carcinoma in situ (DCIS) that arose in axillary lymph nodes excised as the sentinel lymph node from two patients with breast carcinoma. The patient ages were 72 and 36 years and both patients underwent mastectomy and axillary lymph node dissection. In addition to DCIS in the sentinel lymph node, the first patient had a wide DCIS and microinvasion in the ipsilateral breast and a micrometastasis in another sentinel lymph node. The second patient was operated on after neoadjuvant chemotherapy and had DCIS and a small focus of invasion, in addition to invasive and in situ ductal carcinoma in the lymph node having signs of chemotherapy-induced regression. The presence of DCIS was confirmed by use of the immunohistochemical method with antibodies against myoepithelial cells. As a potential source of cellular origin, DCIS was accompanied by benign epithelial cell clusters in the lymph node in both cases. Morphologic and immunohistochemical features were similar in breast and lymph node neoplasms. We conclude that DCIS may rarely develop from benign epithelial inclusions in the axillary lymph node and is a potential diagnostic pitfall in cases having ipsilateral breast carcinoma.
- Open Access
- 1 December 2022
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 39 (4) , 254-261
Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience
Objective: Redditux (R) (RED), as a biosimilar rituximab, was approved in Turkey for all indications of the original Mabthera (R) (MAB) in March 2018. The aim of our study was to evaluate the efficacy and safety of RED in de novo diffuse large B-cell lymphoma. Materials and Methods: Fifty-one patients received RED combined with the CHOP regimen. The median follow-up was 31 months. The historical control group included 219 patients treated with the MAB-CHOP regimen and the median follow-up time was 38 months. We compared the response rates and survival outcomes of these RED-CHOP and MAB-CHOP cohorts. Results: In the RED cohort, the overall response rate (ORR) at the end of the treatment protocol was 86%, with 37 (72.5%) cases of complete response (CR) and 7 (13.5%) cases of partial response (PR). In the historical MAB cohort, the ORR was 84%, with CR and PR rates of 82% and 2%, respectively. The 24-month progression-free survival (PFS) rates were 73.76% (95% confidence interval [CI]: 0.59-0.84) and 85.2% (95% CI: 0.79-0.90) for the RED and MAB cohorts, respectively (p=0.0106). The 24-month overall survival rates were 78.4% (95% CI: 0.64-0.87) and 81.4% (95% CI: 0.75-0.86) for the RED and MAB cohorts, respectively (p=0.7461). For patients with high revised International Prognostic Index scores, 24-month PFS was 45.5% (95% CI: 0.17-0.71) and 63% (95% CI: 0.37-0.80) for the RED and MAB cohorts, respectively (p=0.0711). In the RED cohort, central nervous system (CNS) relapse was significantly increased compared to the MAB cohort (10% vs. 1.83%, p=0.004). Among the RED cohort, bone involvement at the time of diagnosis was a risk factor for CNS relapse (p=0.028). Thirteen patients died in follow-up. There were no serious adverse events causing the cessation of the drugs. Conclusion: RED has an ORR similar to that of MAB. However, PFS rates were worse in the RED cohort. Additionally, CNS relapse ratio was a major concern for our RED cohort. Large prospective controlled studies and real-life data with longer follow-up are needed to document the non-inferiority of RED compared to MAB.
- 1 December 2022
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 39 (4) , 254-261
Open AccessBiosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience
Objective: Redditux (R) (RED), as a biosimilar rituximab, was approved in Turkey for all indications of the original Mabthera (R) (MAB) in March 2018. The aim of our study was to evaluate the efficacy and safety of RED in de novo diffuse large B-cell lymphoma. Materials and Methods: Fifty-one patients received RED combined with the CHOP regimen. The median follow-up was 31 months. The historical control group included 219 patients treated with the MAB-CHOP regimen and the median follow-up time was 38 months. We compared the response rates and survival outcomes of these RED-CHOP and MAB-CHOP cohorts. Results: In the RED cohort, the overall response rate (ORR) at the end of the treatment protocol was 86%, with 37 (72.5%) cases of complete response (CR) and 7 (13.5%) cases of partial response (PR). In the historical MAB cohort, the ORR was 84%, with CR and PR rates of 82% and 2%, respectively. The 24-month progression-free survival (PFS) rates were 73.76% (95% confidence interval [CI]: 0.59-0.84) and 85.2% (95% CI: 0.79-0.90) for the RED and MAB cohorts, respectively (p=0.0106). The 24-month overall survival rates were 78.4% (95% CI: 0.64-0.87) and 81.4% (95% CI: 0.75-0.86) for the RED and MAB cohorts, respectively (p=0.7461). For patients with high revised International Prognostic Index scores, 24-month PFS was 45.5% (95% CI: 0.17-0.71) and 63% (95% CI: 0.37-0.80) for the RED and MAB cohorts, respectively (p=0.0711). In the RED cohort, central nervous system (CNS) relapse was significantly increased compared to the MAB cohort (10% vs. 1.83%, p=0.004). Among the RED cohort, bone involvement at the time of diagnosis was a risk factor for CNS relapse (p=0.028). Thirteen patients died in follow-up. There were no serious adverse events causing the cessation of the drugs. Conclusion: RED has an ORR similar to that of MAB. However, PFS rates were worse in the RED cohort. Additionally, CNS relapse ratio was a major concern for our RED cohort. Large prospective controlled studies and real-life data with longer follow-up are needed to document the non-inferiority of RED compared to MAB.
- Open Access
- 23 September 2022
- Published by Galenos Yayinevi in Journal of Turkish Society of Obstetric and Gynecology
- Vol. 19 (3) , 178-186
Effect of asymptomatic COVID-19 infection on the placenta in the third trimester of pregnancy: A prospective case-control study
To clarify the effect of asymptomatic coronaviruse disease-2019 (COVID-19) positivity on the placenta in the third trimester of pregnancy. This prospective, case-control study included 30 pregnant women diagnosed with asymptomatic COVID-19 between April 30, 2021 and July 20, 2021 who delivered after the 34th gestational week, and a control group of 30 pregnant women without COVID-19, who delivered between April 2021 and July 2021, matched to the study group regarding age, gestational age and body mass index. Outcomes were compared in terms of demographic characteristics, serum blood outcomes, neonatal results, complications and placental histopathological findings. The mean age of the study population was 28.8 years and the mean gestational week was 38.2 weeks. The C-reactive protein levels (38.2 mg/L vs 5.8 mg/L, p=0.001) and ferritin levels (266.4 μg/L and 40.5 μg/L, p=0.001) were significantly higher in the COVID-19-positive pregnant women. The lymphocyte level was significantly higher in the non-COVID-19 pregnant women (p=0.040). Mural hypertrophy was determined at a significantly higher rate in COVID-positive pregnant women (83.3% vs 30.0%, p=0.001). Multivariate regression analysis showed that only COVID-19 positivity increased the presence of mural hypertrophy in pregnant women with asymptomatic COVID-19 (4.716-fold, 95% confidence interval=1.012-22.251). The results of this study demonstrated that asymptomatic COVID-19 had no significant effect on pregnancy and neonatal complications. However, mural hypertrophy in the placenta was found at a significantly higher rate in pregnant women with asymptomatic COVID-19.
- 23 September 2022
- Published by Galenos Yayinevi in Journal of Turkish Society of Obstetric and Gynecology
- Vol. 19 (3) , 178-186
Open AccessEffect of asymptomatic COVID-19 infection on the placenta in the third trimester of pregnancy: A prospective case-control study
To clarify the effect of asymptomatic coronaviruse disease-2019 (COVID-19) positivity on the placenta in the third trimester of pregnancy. This prospective, case-control study included 30 pregnant women diagnosed with asymptomatic COVID-19 between April 30, 2021 and July 20, 2021 who delivered after the 34th gestational week, and a control group of 30 pregnant women without COVID-19, who delivered between April 2021 and July 2021, matched to the study group regarding age, gestational age and body mass index. Outcomes were compared in terms of demographic characteristics, serum blood outcomes, neonatal results, complications and placental histopathological findings. The mean age of the study population was 28.8 years and the mean gestational week was 38.2 weeks. The C-reactive protein levels (38.2 mg/L vs 5.8 mg/L, p=0.001) and ferritin levels (266.4 μg/L and 40.5 μg/L, p=0.001) were significantly higher in the COVID-19-positive pregnant women. The lymphocyte level was significantly higher in the non-COVID-19 pregnant women (p=0.040). Mural hypertrophy was determined at a significantly higher rate in COVID-positive pregnant women (83.3% vs 30.0%, p=0.001). Multivariate regression analysis showed that only COVID-19 positivity increased the presence of mural hypertrophy in pregnant women with asymptomatic COVID-19 (4.716-fold, 95% confidence interval=1.012-22.251). The results of this study demonstrated that asymptomatic COVID-19 had no significant effect on pregnancy and neonatal complications. However, mural hypertrophy in the placenta was found at a significantly higher rate in pregnant women with asymptomatic COVID-19.
- 4 April 2022
- Published by Springer Nature in Journal of Hematopathology
- Vol. 15 (2) , 75-81
Protein kinase c delta expression in primary central nervous system lymphomas
- 4 April 2022
- Published by Springer Nature in Journal of Hematopathology
- Vol. 15 (2) , 75-81
Protein kinase c delta expression in primary central nervous system lymphomas
- 1 December 2021
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 55, 151830
Diagnostic accuracy of core biopsies of renal masses: Experience in a real-life setting from a tertiary center
- 1 December 2021
- Published by Elsevier in Annals of Diagnostic Pathology
- Vol. 55, 151830
Diagnostic accuracy of core biopsies of renal masses: Experience in a real-life setting from a tertiary center
- 1 September 2021
- Published by Kare Publishing in İstanbul Kanuni Sultan Süleyman Tıp dergisi
- Vol. 13 (3) , 194-198
R-CHOP Chemotherapy with a Rituximab Biosimilar (Redditux®) for Patients with de novo Diffuse Large B-cell Lymphoma: First Preliminary Results of a Real-Life Single-Center Experience from Turkey
- 1 September 2021
- Published by Kare Publishing in İstanbul Kanuni Sultan Süleyman Tıp dergisi
- Vol. 13 (3) , 194-198
R-CHOP Chemotherapy with a Rituximab Biosimilar (Redditux®) for Patients with de novo Diffuse Large B-cell Lymphoma: First Preliminary Results of a Real-Life Single-Center Experience from Turkey